FDA Approves Zejula for Advanced Ovarian Cancer Subset

October 23, 2019 3:30 pm

By Jessica Skarzynski

The Food and Drug Administration has approved Zejula for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer that have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous Read more

New Program Helps Patients with Advanced Cancer Access Experimental Drugs

July 11, 2019 7:00 pm

By Jack Elliot

In June 2019, the FDA announced a new program called “Project Facilitate” that is designed exclusively for patients with advanced cancer who have exhausted all available treatment options and are unable to participate in clinical trials. Through Read more

Types of Drugs Used to Treat Cancer

April 15, 2019 7:00 pm
By Andrea S. Blevins Primeau, PhD, MBA There are many different types of agents used in the treatment of cancer, and they can generally be classified according to molecule type or their basic mechanism of action. Different cancer types have… Read more

FDA Approves Lynparza for Maintenance Treatment of BRCA-Mutant Gynecologic Cancers

December 19, 2018 5:00 pm

By Brielle Benyon

The Food and Drug Administration (FDA) approved Lynparza (olaparib) for the maintenance treatment of adults with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in a

Read more

What Are My Options for Ovarian Cancer Treatment?

December 15, 2018 9:00 am

By Korin Miller

Navigating ovarian cancer treatment options can be overwhelming, but if you have this illness, it’s a part of the process.

There are five major forms of treatment for ovarian cancer. However, the type of ovarian cancer you … Read more

Many Americans Unaware of Promise of Targeted, ‘Personalized’ Medicine

December 7, 2018 7:00 pm

By Dennis Thompson

Medical science has made tremendous advances in “personalized medicine” — drugs that fight cancer and other diseases by boosting the immune system or targeting specific genetic traits.

Former U.S. President Jimmy Carter benefited from one of these

Read more

From Standard to Personalised Care

November 17, 2018 7:00 pm

Woman with ovarian cancer has incredible response to treatment selected based on her tumor molecular profile. This tumor testing is part of the tumor blueprint that Clearity provides.

By Pierre Valette

“It was definitely a ‘holy smokes’ moment,” recounts Justin … Read more

Taking A Wider View Of Precision Oncology

August 6, 2018 11:06 pm

Proponents of precision medicine cite the growing numbers of successful precision cancer drugs. The examples of Herceptin (trastuzumab), Gleevec (imatinib mesylate), Xalkori (crizotinib), and Zelboraf (vemurafenib) come to mind. Skeptics, on the other hand, focus on the … Read more

FDA Approves Bevacizumab Plus Chemotherapy in Advanced OC

June 14, 2018 7:32 pm

Today, the U.S. Food and Drug Administration (FDA) approved bevacizumab (Avastin) in combination with chemotherapy (carboplatin and paclitaxel) followed by bevacizumab as a single agent for the treatment of women with advanced (stage III or IV) ovarian cancer following initial … Read more

FDA Clears Paxman Scalp-Cooling System

June 12, 2018 6:23 pm

The FDA granted expanded clearance to the Paxman Scalp Cooling System, allowing the device to be used by patients with any type of solid tumor.

The Paxman Scalp Cooling System (Paxman) — designed to reduce hair loss among patients who … Read more

FDA Approves Rubraca for Maintenance Ovarian Cancer Treatment

April 6, 2018 8:05 pm

The Food and Drug Administration (FDA) approved Rubraca (rucaparib) as a maintenance therapy for women with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy, according to Clovis Oncology, the … Read more

SGO 2018: Putting PARP Inhibitor Perspectives Into Practice

March 28, 2018 9:28 pm

Achieving consensus on which poly (ADP-ribose) polymerase (PARP) inhibitor to use and when during management of ovarian cancer proved challenging Sunday for 4 oncologists who took attendees through a lively discussion of applying current standards from professional societies to everyday … Read more

FDA Approves 23andMe Cancer Test For BRCA Genes

March 12, 2018 8:33 pm

The home DNA testing company 23andMe has received approval from the US Food and Drug Administration (FDA) to test for three genetic mutations in two genes that you have probably heard of if you know who Angelina Jolie is, BRCA1 … Read more

FDA Grants Priority Review for Rucaparib

December 28, 2017 8:08 pm

The US Food and Drug Administration (FDA) has granted priority review status to rucaparib as maintenance therapy for women with recurrent ovarian cancer, according to the drug’s developer. The application is for women who are platinum sensitive, and in complete … Read more

Tumor Profiling Panel Undergoes Simultaneous FDA, CMS Review

December 9, 2017 12:04 am

The US Food and Drug Administration (FDA) has approved a cancer diagnostic test, FoundationOne CDx (F1CDx, Foundation Medicine), for use in detecting 300-plus genetic mutations in any solid tumor. At the same time, the Centers for Medicare & Medicaid Services … Read more

Precision Medicine: A New Era for Ovarian Cancer

September 6, 2017 4:46 pm

By: Laura L. Holman, MD, MS

We’ve come a long way in treating ovarian cancer. This treatment has historically consisted of debulking surgery for nearly every patient, but it is evolving to become more informed and precise. Diagnostic laparoscopy, for … Read more

PARP Inhibitors Changing the Landscape of Ovarian Cancer Treatment

July 11, 2017 5:53 pm

With the FDA approval of two new PARP inhibitor drugs since last year’s Ovarian Cancer National Conference, it’s no surprise the topic was of great interest at this year’s meeting in Chicago, and a standing-room-only crowd was on hand July … Read more

Avastin Gains Expanded FDA Approval for Platinum-Sensitive Ovarian Cancer

December 8, 2016 7:04 pm

Avastin (bevacizumab) gained an expanded FDA approval to treat patients with platinum-sensitive recurrent ovarian cancer as a part of a combination regimen with chemotherapy followed by continued use of the angiogenesis inhibitor, according to the drug developer, Genentech.

The approval … Read more